Wall Street analysts expect that Phio Pharmaceuticals Corp. (NASDAQ:PHIO) will post earnings of ($0.32) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Phio Pharmaceuticals’ earnings. Phio Pharmaceuticals reported earnings per share of ($0.41) during the same quarter last year, which would indicate a positive year-over-year growth rate of 22%. The business is expected to issue its next quarterly earnings results on Thursday, March 24th.
According to Zacks, analysts expect that Phio Pharmaceuticals will report full year earnings of ($1.11) per share for the current fiscal year. For the next fiscal year, analysts anticipate that the business will report earnings of $0.98 per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover Phio Pharmaceuticals.
Phio Pharmaceuticals (NASDAQ:PHIO) last posted its earnings results on Wednesday, November 10th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.03).
Hedge funds have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP grew its position in shares of Phio Pharmaceuticals by 38.3% during the first quarter. Dimensional Fund Advisors LP now owns 34,808 shares of the company’s stock worth $93,000 after acquiring an additional 9,631 shares during the last quarter. Virtu Financial LLC grew its position in shares of Phio Pharmaceuticals by 74.7% during the second quarter. Virtu Financial LLC now owns 27,110 shares of the company’s stock worth $61,000 after acquiring an additional 11,588 shares during the last quarter. Goldman Sachs Group Inc. purchased a new position in shares of Phio Pharmaceuticals during the second quarter worth approximately $43,000. Geode Capital Management LLC grew its position in shares of Phio Pharmaceuticals by 22.5% during the third quarter. Geode Capital Management LLC now owns 107,192 shares of the company’s stock worth $216,000 after acquiring an additional 19,691 shares during the last quarter. Finally, Cetera Investment Advisers purchased a new position in shares of Phio Pharmaceuticals during the third quarter worth approximately $61,000. 5.19% of the stock is currently owned by institutional investors.
Shares of NASDAQ PHIO traded down $0.02 during mid-day trading on Thursday, reaching $1.42. The company’s stock had a trading volume of 80,283 shares, compared to its average volume of 760,139. The stock has a 50-day moving average of $1.75 and a two-hundred day moving average of $1.92. The stock has a market capitalization of $19.22 million, a P/E ratio of -1.17 and a beta of 1.96. Phio Pharmaceuticals has a 1-year low of $1.32 and a 1-year high of $4.36.
About Phio Pharmaceuticals
Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics that addresses unmet medical needs. Its clinical product candidate includes RXI-109, an RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.
Recommended Story: Dividend Kings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.